Isotretinoin (Accutane) and Depression / suicidal ideation: is the FAERS signal real?
Isotretinoin (Accutane) ↔ Depression / suicidal ideation
Reporting over time (stimulated-reporting check)
Reporting spiked in 2011, 2012 — 38% of all 5,698 reports arrived in two years (2011–2012). A burst like this usually follows a regulatory communication, media coverage or litigation advertising rather than a change in the drug's effect; it inflates disproportionality for those years.
Bars: reports per year as a share of all FAERS reports for this drug, 2004–2025; amber = spike year (>3× the median share, ≥50 reports). Source: openFDA count=receivedate, retrieved 2026-10-09.
Isotretinoin carries a prominent psychiatric warning on its U.S. label, and individual case reports of depression and suicidal ideation following treatment are well documented and plausible (isotretinoin affects retinoid signaling pathways implicated in mood regulation). But the two largest cohort studies on this question directly disagree with each other, and that disagreement is the real story. Jick et al. (2000) followed 7,195 Saskatchewan isotretinoin users and 13,700 acne patients on oral antibiotics (plus a smaller UK cohort), comparing depression/psychosis diagnoses before vs. after exposure, and found relative risks around 1.0 — no detectable excess. Sundström et al., a Swedish registry cohort of 5,756 isotretinoin patients, found the opposite framing of the same question: the standardized incidence ratio for attempted suicide was already elevated in the year before treatment started (SIR 1.57 for all attempts), not just during or after it — the single clearest documented instance of the confounding-by-indication pattern this grade is built on (people with the most psychologically distressing acne are the ones referred for isotretinoin in the first place). Note also that completed suicide specifically is not a flagged signal in this dataset (PRR 1.3), which argues against the most severe form of the proposed association, even while the milder mood-symptom signals remain flagged. This page grades it as genuinely contested rather than established in either direction.
Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol. 2000;136(10):1231–1236. PMID 11030769. Sundström A, et al. Association of suicide attempts with acne and treatment with isotretinoin. BMJ. 2010;341:c5812.
| Bradford Hill viewpoint | Status | Note |
|---|---|---|
| Temporality (necessary) | partial | Mixed — several studies find depression risk highest before treatment starts |
| Strength | partial | PRR 10–11, modest |
| Consistency | not established | Published cohort studies disagree with each other |
| Specificity | not established | Depression is also elevated in acne patients not on isotretinoin |
| Biological gradient | not established | No consistent dose-response shown |
| Plausibility | partial | Retinoid-signaling/mood hypothesis proposed, not confirmed |
| Coherence | partial | A competing hypothesis (disease severity, not drug) fits the same data equally well |
| Experiment | not established | No clean dechallenge/rechallenge trial data |
| Analogy | not established | — |
This page's own qualitative read, not an automated/citation-gated assessment.